SCHEMBL581257

SCHEMBL581257

OB(O)c1cc(F)c(F)cc1F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29419677 1.00
SCHEMBL28824845 0.94
SCHEMBL503015 0.91
SCHEMBL9939118 0.85 ALDH1A1 (0.36)
Hydrochloric Acid SCHEMBL20703175 0.83 ALDH1A1 (0.34)
SCHEMBL1146375 0.81 DAO (0.32)
SCHEMBL21543209 0.81 CA3 (0.37)
SCHEMBL2914323 0.81 DAO (0.32)
SCHEMBL29955299 0.81 DAO (0.32)
SCHEMBL17181777 0.81 CA3 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8361484-B2 Polymer systems for lung volume reduction therapy AERIS THERAPEUTICS, INC. (US) 2013-01-29 US claimed
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy CANADIAN IMPERIAL BANK OF COMMERCE (CA) 2010-02-18 US claimed
EP-2059227-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY Aeris Therapeutics, Inc. (US) 2009-05-20 EP claimed
WO-2008039827-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY AERIS THERAPEUTICS, INC. (US) 2008-04-03 WO claimed
US-20260103459-A1 SUBSTITUTED AZACYLES AS TRPM8 MODULATORS GIVAUDAN SA (CH) 2026-04-16 US disclosed
US-12559454-B2 Benzenesulfonamide derivatives and uses thereof 2692372 ONTARIO, INC. (CA) 2026-02-24 US disclosed
EP-4146220-B1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE AMGEN INC (US) 2026-02-18 EP disclosed
US-12528801-B2 Substituted azacyles as TRPM8 modulators GIVAUDAN SA (CH) 2026-01-20 US disclosed
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-12-25 US disclosed
US-12497389-B2 Organic electroluminescence device and heterocyclic compound for organic electroluminescence device SAMSUNG DISPLAY CO., LTD. (KR) 2025-12-16 US disclosed
US-12448388-B2 PRMT5 inhibitors and uses thereof GILEAD SCIENCES, INC. (US) 2025-10-21 US disclosed
US-20250304580-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2025-10-02 US disclosed
WO-2008060488-A1 TRICYCLIC HETEROAROMATIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO., INC. (US) 2008-05-22 WO disclosed
WO-2008039827-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY AERIS THERAPEUTICS, INC. (US) 2008-04-03 WO disclosed
EP-1888066-A2 AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES Merck and Co., Inc. (US) 2008-02-20 EP disclosed
US-20070254865-A1 2-substituted phenyl-5-fused heteroaryl cyclohexylamines; may be coadministered with metformin; non-insulin dependent diabetes MERCK SHARP & DOHME LLC 2007-11-01 US disclosed
WO-2007076835-A1 METHOD FOR PRODUCTION OF $G(A),$G(B)-UNSATURATED CARBOXYLATE DERIVATIVES STUDIENGESELLSCHAFT KOHLE MBH (DE) 2007-07-12 WO disclosed
EP-1761532-A1 AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES Merck & Co., Inc. (US) 2007-03-14 EP disclosed
WO-2006127530-A2 AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO., INC. (US) 2006-11-30 WO disclosed
WO-2006009886-A1 AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES MERCK & CO., INC. (US) 2006-01-26 WO disclosed